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Abstract
Background: Traumatic brain injury (TBI) is one of the major health and socioeconomic problems in the world.
Immune-enhancing enteral formula has been proven to significantly reduce infection rate in TBI patients. One of
the ingredients that can be used in immunonutrition formulas to reduce inflammation and oxidative stress is
pycnogenol.
Objective: The objective of this work is to survey the effect of pycnogenol on the clinical, nutritional, and
inflammatory status of TBI patients.
Methods: This is a double-blind, randomized controlled trial. Block randomization will be used. An intervention
group will receive pycnogenol supplementation of 150mg for 10 days and a control group will receive a placebo for
the same duration. Inflammatory status (IL-6, IL- 1β, C-reactive protein) and oxidative stress status (malondialdehyde,
total antioxidant capacity), at the baseline, at the 5th day, and at the end of the study (10th day) will be measured.
Clinical and nutritional status will be assessed three times during the intervention. The Sequential Organ Failure
Assessment (SOFA) questionnaire for assessment of organ failure will be filled out every other day. The mortality rate
will be calculated within 28 days of the start of the intervention. Weight, body mass index, and body composition will
be measured. All analyses will be conducted by an initially assigned study arm in an intention-to-treat analysis.
Discussion: We expect that supplementation of 150mg pycnogenol for 10 days will improve clinical and nutritional
status and reduce the inflammation and oxidative stress of the TBI patients.
Trial registration: This trial is registered at clinicaltrials.gov (ref: NCT03777683) at 12/13/2018.
Keywords: Traumatic brain injury, Critical care, Pycnogenol, Inflammation, Nutrition support, French maritime pine bark
extract
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Background
Traumatic brain injury
Traumatic brain injury (TBI) is one of the major health
and socioeconomic problems in the world [1]. It is
prevalent in both developed and developing societies
and affects people of all ages. TBI is called the ‘silent
epidemic’ because problems resulting from TBI do not
occur immediately [2]. TBI causes about 1.5 million
deaths and hospitalizations per year in the USA [3]. TBI
is more common among teens and young adult aged
15–45 years, mainly due to road accidents and sport-
related events. Men are three times more likely to be in-
jured and more severely damaged [4].
TBI is used instead of ‘head injury’ because it shows
the importance of the ‘brain’ [5]. TBI is defined as: ‘An
alteration in brain function or physiology due to external
force or shock from the outside [6]. Patients with TBI
are categorized into three groups based on the Glasgow
Coma Scale: mild, moderate, and severe. The Glasgow
Coma Scale (GCS) is a system used to assess coma and
impaired consciousness [7]. A GCS score of 13–15 is de-
fined as mild, 9–12 as moderate, and 3–8 as severe [7].
The mechanisms of damage to the brain tissue associ-
ated with TBI are classified into two categories: primary
and secondary. Primary damage is due to the mechanical
force involved in the skull and the brain, which seems to
be irreversible [8]. The primary injury complications in-
clude: brain contusions, axonal injuries, rupturing of
blood vessels, and intracranial hemorrhages. Secondary
injury complications progress over time [9]. The second-
ary injury complications include: elevated intracranial
pressure, blood–brain barrier (BBB disruption, neuroin-
flammation, brain edema, cerebral hypoxia, ischemia,
and delayed neurodegeneration [10–12].
Neuroinflammation in TBI
Cytokines, chemokines, and growth factors have proven
to play important roles in the pathophysiology of TBI.
Immediately after brain injury, proinflammatory cyto-
kines, such as IL-1β, IL-6, and tumor necrosis factor-α
(TNF-α) as well as transforming growth factor-beta
(TGF-β) are produced in large volume. These worsen
the condition of trauma and delay the recovery by pro-
ducing oxidative stress and matrix metalloproteinases
[13, 14]. These post-traumatic inflammatory cascades
cause blood–brain barrier (BBB) dysfunction, which ul-
timately leads to the influx of inflammatory cells from
the blood to the brain [15]. Production of reactive oxy-
gen substrates (ROS) directly or indirectly, as oxidative
by-products of lipids, proteins, or nucleic acids are com-
mon following traumatic brain injury. Malondialdehyde
(MDA) is the major by-products of lipid peroxidation.
MDA is potentially an atherogenic lipid peroxide and
generated in vivo via peroxidation of polyunsaturated
fatty acids [16].
Nutrition support in TBI
Nutritional support is an important issue in intensive
care for critically ill patients such as those with TBI.
Patients with TBI often remain in a hypermetabolic
state where the energy expenditure is increased [17].
Early nutrition support in TBI patients results in a
significant reduction in mortality rate, less infectious
complications, and lower risk of poor outcome [18].
There has been a growing use of immunonutrition to
modulate the inflammatory response in injury or
infection and to improve clinical outcomes [19].
Immune-modulation enteral formula has been proven
to significantly reduce infection rate in TBI patients
[20]. One of the ingredients that can be used in an
immunonutrition formula to reduce inflammation and
oxidative stress is pycnogenol.
Pycnogenol
Pycnogenol® (PYC) is recognized as one of the most
powerful natural antioxidants, which is a bark extract of
the French maritime pine (Pinus pinaster) and is rich in
flavonoids. The main components of PYC are: polyphe-
nols, specifically mono- and oligomeric units of caffeic
acid, ferulic acid, catechin, epicatechin, and taxifolin
[21]. It is classified as GRAS (generally recognized as
safe) in the USA [22]. Clinical effects of PYC include
endothelium-dependent vasodilator activity [23] and
anti-thrombotic effect as shown by numerous in vitro
and in vivo investigations in animals and human clinical
research studies [21, 24]. PYC prevents neurotoxicity
and apoptotic cell death in oxidative stress status [25,
26]. Also, PYC protects against lipid peroxidation and
pro-oxidants and peroxynitrites [27, 28]. A number of
animal studies have proven the protective effect of PYC
following traumatic brain injury by suppressing IL-6 and
TNF-α levels [29, 30]. No serious adverse effects have
been seen in any clinical trials or commercial use [31].
The most commonly observed adverse effect is gastric
discomfort due to its mild and transient nature [22].
Recently, we conducted a systematic review and meta-
analysis of clinical trials that used PYC in chronic
diseases [32]. Our meta-analysis revealed that PYC sup-
plementation may have beneficial effects on glycolipid
metabolism by reducing fasting glucose, HbA1c, LDL,
and enhancing HDL. Also, PYC reduced CRP, plasma-
free radicals, systolic and diastolic blood pressure, and
body mass index. In this study, for the first time in the
world we aimed to assay the PYC effect on inflammatory
markers and clinical status in acute phase in humans.
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Objectives
Main objective
Previous human studies have reported the neuroprotec-
tive and anti-inflammatory effects of PYC. The effect of
PYC to reduce neuroinflammation in TBI rat has also
been proven. So the main objective of the present study
is to study the effect of PYC on the clinical, nutritional,
and inflammatory status of TBI patients as the first hu-
man study in the world.
Specific objectives
In achieving this overall goal, numerous issues will be
addressed with the specific objective of providing defini-
tive answers to the following questions: (1) Is PYC
effective in reducing the inflammatory markers including
IL-6, IL-1β, and CRP (C-reactive protein) in TBI patients
in an intensive care unit? (2) Is PYC effective in reducing
oxidative stress in TBI patients? (3) Is PYC effective in
improving the clinical status of TBI patients by
improving the APCHE II (Acute Physiology And
Chronic Health Evaluation II) (Additional file 1: Table
S1) and SOFA (Sequential Organ Failure Assessment)
(Additional file 1: Table S2) Score? (4) Is PYC effective
in improving anthropometric indices (weight and body
composition) and nutritional score measured via
NUTRIC score questionnaire? (5) Is PYC effective in
reducing 28-day mortality in TBI patients?
Trial deign
This is a parallel-group randomized trial. Blocked
randomization will be used to allocate eligible partici-
pants to either the control group or the intervention
group. The study framework is superiority.
Methods/design
Patient selection
Inclusion criteria
All TBI patients admitted directly or transferred to the
intensive care units of the participating hospital will be
evaluated for eligibility for entry into the randomized
clinical trial. Preliminary eligibility criteria are summa-
rized in Table 1.
Exclusion criteria
Patients meeting all preliminary eligibility criteria are
considered potentially eligible for the study. Patients are
screened for the presence of any specific exclusion
criteria which would preclude study entry. These exclu-
sions are designed to eliminate patients for whom par-
ticipation may be dangerous or patients with serious
medical disorders whose impact on operative outcome
may obscure the importance of nutritional, clinical, and
inflammatory factors. These are summarized in Table 2.
Default criteria
Once randomization has taken place, patients will be re-
moved from the study only for the following reasons: (1)
patient’s or physician’s request, (2) significant change in
patient’s treatment process, (3) create any exclusion
criteria, (4) sensitivity to PYC supplementation.
Sample size
Sample-size calculations were based upon Luzzi et al.ʼs
study [33], which showed that the mean CRP change in
the treatment group was 60% and the control was
unchanged or up to a maximum of 15%. Based on the
formula for comparing two proportions of a qualitative
attribute from two independent statistical societies, the
sample size was determined as 25 individuals in each
group, (α = 0.05, β = 0.1, the power of study is 90%).
Assuming a probable drop out of the sample, 30 patients
in each group will be considered.
A study evaluating the effect of PYC on IL-6 and
TNF-α in TBI was an animal study [29] and inappropri-
ate for the human sample-size calculation. Therefore, we
used CRP as an inflammatory factor to calculate the
sample size. However, for more certainty, we calculated
the sample size according to Hakumat Rai et al.ʼs study
[17] based on IL-6 change in TBI patients. Based on the
mean difference between the two groups for IL-6 and
error level of 5% and power of 85%, the total sample size
calculated was 46. With a 10% probability of drop out
Table 1 Primary criteria for study eligibility
Admission in ICU a due to TBI b
18 year ≤ age≤ 65 year
GCS c score > 8
Stable hemodynamic and metabolic status in the first 24 to 48 h
Having enteral nutritional support
Fill out the informed consent form by the patient or first-degree rela-
tives of the patient
a Intensive care unit. b Traumatic brain injury. c Glasgow Coma Scale
Table 2 Exclusion criteria
Pregnancy and lactation
Morbid obesity: BMI a ≥ 40
Failure to start enteral nutrition in the first 24–48 h
Suffering from autoimmune disorders and HIV/AIDS
Suffering or having history of cancer and any liver failure
Receiving positive inotropic medications including dopamine,
dobutamine, and epinephrine
Severe and active bleeding
Suffering from sepsis
Having a history of known food allergies
a Body mass index
Malekahmadi et al. Trials          (2020) 21:162 Page 3 of 9
during the study, the total sample size was 50 (25 in
each group).
Study procedures
The university’s executive committee will oversee the
project’s implementation and progress, information se-
curity, safety of trial participants, and scientific impact
assessment. Also this committee will review data from
the trial. The trial sponsor will undertake auditing of the
trial procedure.
Randomization and masking
We will randomly allocate eligible patients on enrolment
[1] to either the control group or the intervention group.
The randomization list of unique patient identifiers is
generated by the computer-generated random block size
site. The classification is based on age (18 to 40 and 40
to 65 years old), gender (male / female) and APACHE II
score (0 to 35 and 35 to 71) using quadruple blocks.
Nutritionists or clinicians will keep the sealed opaque
envelope containing the unique patient identifier and
the study group allocation in a locked cabinet in the
study laboratory. They will be opened by the second
nutritionist. Investigators, all study staff hospital attend-
ing clinical teams, and patients will be masked to the
study group allocation.
Intervention
A pragmatic [34], parallel-group, double-blind, random-
ized controlled trial (Table 3) will be conducted. We will
enroll 60 patients who are admitted to the ICU at a
university hospital in Tehran, Iran. All participants or
their first-degree relatives will need to provide informed
consent to the clinician before participating. Participants
will be randomly divided into two groups. The method
of randomization and masking are explained above. At the
first visit, baseline data will be gathered and the interven-
tion group will receive PYC supplement (OLIGOPIN) in
the form oral capsules containing 50mg French maritime
pine bark extract plus 130mg microcrystalline cellulose.
OLIGOPIN powder of each capsule will be dissolved in
10ml of deionized water and given to patients via gavage
(three capsules per day) for 10 days.
The control group will receive oral capsules con-
taining 130 mg microcrystalline cellulose with 10 ml
of deionized water via gavage (three capsules per day)
for 10 days.
The capsules will be given by the investigator to the
patients by gavage, so fidelity to the intervention will be
strong. However, for more certainty, at the end of each
day, the number of capsules remaining for each patient
will be checked. In order to control the confounding
effect of food intake, both the control group and the
intervention group receive the standard formulas based
on their daily required energy via enteral root feeding.
Possible risk assessment of intervention
Initially, an intervention with a dose of 150 mg of PYC
will be started for ten patients, and in the absence of
clinical complications and observing the expected effect
on the reduction of inflammatory markers, the same
dose will be continued. Otherwise, it will be reduced to
100 mg, if there is any adverse effect. There have been
no reports of serious adverse events in any clinical trials
or commercial use of OLIGOPIN. However, these pa-
tients will be regularly evaluated biochemically and clin-
ically each day, and the liver function tests including
serum levels of ALT (alanine aminotransferase) and AST
(aspartate aminotransferase) will be checked. If there are
any potential complications from intervention or if the
physician determines that the intervention should be
Table 3 Nine PRECIS-2 domains for trial designing characteristics
Domain Considerations
Eligibility All eligible TBI a patients admitted directly or transferred to the ICU b of participating hospital will take PYC c
along with their routine treatment
Recruitment path Pragmatic recruitment through usual visit of patients in ICU
Setting All tests and evaluation status of patients in this trials are performed routinely as a part of usual care, except
specialized test including: IL-6 d, IL-1β e, MDA f, and TAC g
Organization ICU that has intensivist and its trained stuff
Flexibility in delivery PYC will be prescribed with gavage
Flexibility in adherence After the written consent of the patient or his/her companion, PYC will be prescribed by the intensivist and
will be gavaged by the nurse. PYC is a dietary supplement and it does not interfere with other medications
and will be given as part of the patient’s nutritional formula
Follow-up Usual follow-up that is performed for critically ill patients will be done in this trial; also, a 28-day follow-up for
mortality will be performed
Primary outcome All outcome directly are related to clinical status of patients
Primary analysis Intention-to-treat with all available data will be used for analysis
a Traumatic brain injury. b Intensive care unit. c Pycnogenol. d Interleukin-6. e Interleukin-1β. f Malondialdehyde. g Total antioxidant capacity
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discontinued, the supplements will be immediately re-
moved from the patient’s enteral nutrition.
Data collection
Data will be collected at four main times: at baseline, at
the 5th day of intervention, at the 10th day of interven-
tion, and at the 28-day follow-up visit. At baseline,
demographic characteristics are gathered via a question-
naire. Anthropometric assessment including height (via
ulna length), weight (by using portable scale “Balas”),
body mass index and body composition (by using bio
impedance device “Inbody”) will be measured at base-
line, the 5th day, and at the end of the intervention.
In order to evaluate inflammatory and oxidative stress
markers, 10 cc of venous blood will be taken from each
patient at the baseline, at the 5th day, and at the end of
the study. The serum sample will be isolated and used to
measure the markers via ELISA kits. APACHE ІІ (for as-
sessment of clinical status of patients) and NUTRIC
questionnaires (for assessment of nutritional status) will
be filled out at the base line, 5th day, and the end of
study. The SOFA questionnaire (for assessment of organ
failure) will be filled out every other day. The mortality
rate will be asked by phone within 28 days of the start of
the intervention. A SPIRIT diagram of the recom-
mended content for the schedule of enrolment, interven-
tions, and assessments is shown in Fig. 1.
Fig. 1 SPIRIT diagram of recommended content for the schedule of enrolment, interventions, and assessments
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Data management
Specially designed forms will be completed by study staff
at each time point, and scanned, verified, and committed
to a local site database within 48 h of completion. Com-
pleted forms will be stored as the source documentation
in a locked cabinet, with access restricted to specified
study team members. The forms will be identified by a
unique participant ID number and will not contain any
patient identifiable information. Queries based on data
in the database will be generated daily, including date,
range, and logic checks.
Outcomes
The measurable outcomes are summarized in Table 4.
Statistical methods
The trial profile will be summarized using a CONSORT
flow chart, including reasons for non-eligibility and non-
enrolment [35]. The objective of this clinical trial is to
determine if PYC supplementation improves clinical and
nutritional outcomes in TBI patients admitted to an ICU
or not. To answer this question, the outcomes of pa-
tients receiving PYC supplements will be compared with
the outcomes of patients receiving placebo.
All analyses will be conducted by initially assigned
study arm in an intention-to-treat analysis, and adjusted
for randomization site. Thus, all randomized patients
who will receive at least one dose of study treatment and
who will have both a baseline and at least one post-
baseline measurement will be analyzed. The data will be
expressed as mean ± SD. Statistical analyses will be con-
ducted with SPSS version 19 (SPSS Institute, Chicago,
IL, USA). Chi-square test will be done for categorical
variables. t test will be done to assess the statistical
significance of the continuous variables. Comparable
nonparametric test (Mann–Whitney U test) will be
substituted when tests for normality and equal variance
failed. A value of p = 0.05 will be used as a criterion for
statistical significance. Survival analysis will be per-
formed with log-rank test. The study design flow dia-
gram is summarized in Fig. 2. More details about the
statistical analyses plan is presented in Additional file 2.
Discussion
The purpose of this trial is to establish proof of concept of
the efficacy of Oligopin in patients with TBI (GCS score >
8). Patients will be screened and randomly enrolled into
the intervention and control groups based on age, gender,
and APACHE II score. Adding Oligopin to a nutritional
formula might reduce neuroinflammation and oxidative
stress and improve clinical and nutritional status in TBI
patients. However, human study about PYC (Oligopin) in
this patient group has not been done so far.
It is assumed that oxidative stress mediated through the
superoxide radical (superoxide) and other reactive oxygen
species (ROS) may be principal to inflammation and im-
paired neural function [36]. The acute inflammatory re-
sponse differs in early and late stages of TBI; too much
inflammation for too long delays recovery [37]. Shortly
after brain injury, there is mass production of proinflam-
matory cytokines, such as IL-1β, IL-6, and CRP [38].
In the event of TBI, IL-1β is the most studied cytokine.
Glial cells produce IL-1β and affect neurons and other
brain cells. IL-1β motivates inflammatory responses and
aggregates immune cells, disrupts the BBB, and forms
edema, and leads to loss of neurons [39]. The high level
of IL-1β has been detected in CSF and brain tissue
within the early hours of a brain injury in humans as
well as in experimental animals [39]. Administration of
anti-IL-1β antibodies decreased edema and degradation
of brain tissue. A previous study reported improvement
of cognitive function in rats following TBI [40]. There
are similar findings for IL-6. Intervention to mitigate IL-
6 in animals with mild TBI triggers normal brain
function and reduces the effects of hypoxia (aggrava-
tion of inflammation of brain damage) [41]. In TBI
patients, CRP levels are correlated with the duration
of hospitalization in an ICU and dependence on a
ventilator, and the severity of the damage [42]. Fi-
nally, we selected these inflammatory factors as out-
comes of the study.
Table 4 Measurable outcomes
Outcome Time frame Measurement method
Change of inflammatory
markers: IL-6 a, IL-1β b
5 and 10 days ELISA kit
Change of inflammatory
marker: CRP c
5 and 10 days Auto analyzer
Change of oxidative
stress markers: MDA d, TAC e
5 and 10 days Calorimetry*
Change of weight 5 and 10 days Portable scale “Balas”
Change of body fat
percentage
5 and 10 days Bio impedance device
“Inbody”
Change of body mass index 5 and 10 days Equation
Change of APCHE ІІ f score 5 and 10 days APCHEІІ score
questionnaire
Change of SOFA g score 3, 5, 7, 9, 10 day SOFA score
questionnaire
Change of NUTRIC score 5 and 10 days NUTRIC score
questionnaire
28-day mortality 28 days Telephone follow-up
a Interleukin-6. b Interleukin-1β. c C-reactive protein. d Malondialdehyde. e Total
antioxidant capacity f Acute physiologic and chronic health evaluation II. g
Sequential organ failure assessment
*Colorimetry is a scientific technique that is used to determine the
concentration of colored compounds in solutions by the application of the
Beer–Lambert law, which states that the concentration of a solute is
proportional to the absorbance
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Duration of intervention
In this study, we selected 10 days for intervention.
According to previous studies, the odds of survival in
the first 10 days of admission of the patients in the
ICU have a declining slope and after 10 days the slope
of the decline will be milder [43, 44]. Therefore, any
intervention of treatment in this period (the first 10
days), which leads to a reduction in the risk of mor-
tality, has great importance. On the other hand, the
duration of intervention used in clinical trials to
evaluate the clinical effects of PYC supplementation
has varied from several hours to several months [22,
45, 46]. So in this study we expect to see the ex-
pected effects after 10 days.
Dose of supplementation
The average dose used in most human studies that
has beneficial effects in improving inflammation is
150 mg [22, 47, 48]. No side effects have been re-
ported with this dose. Therefore we chose 150 mg
Oligopin for this study.
Fig. 2 Study design flow diagram
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Trial status
This trial is registered at clinicaltrials.gov (ref:
NCT03777683) on December 17, 2018, and is ongoing.
It is the first version of the protocol. In April 2019, re-
cruitment began, and the anticipated date to complete
the study is February 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-4008-x.
Additional file 1: Table S1. APCHE II (Acute Physiologic and Chronic
Health Evaluation II) score content. Table S2. SOFA (Sequential Organ
Failure Assessment) score content.
Additional file 2. Statistical analysis plan.
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